Profile data is unavailable for this security.
About the company
Transgene SA is a biopharmaceutical company. The Company designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The Company has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The Company also has various other programs based on its viral vector technology in research or in pre-clinical or clinical development. The Company's activities are focused on human health and, in particular, the research and development of immunotherapy products, including therapeutic vaccines and oncolytic viruses in the field of cancer and infectious diseases. The Company's principal products include TG4010 (MVA-MUC1-IL2), Pexa-Vec (VV-TK-GM-CSF), TG6002 (VV-TK-RR-FCU1), TG1050 (Ad5-HBV) and TG4001 (MVA-HPV-IL2).
- Revenue in EUR (TTM)--
- Net income in EUR--
- Incorporated1979
- Employees162.00
- LocationTransgene SA400 Boulevard Gonthier d'AndernachParc d'Innovation - CS80166ILLKIRCH-GRAFFENSTADEN 67405FranceFRA
- Phone+33 388279100
- Fax+33 388279111
- Websitehttps://www.transgene.fr
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fermentalg SA | 8.04m | -14.14m | 25.42m | 58.00 | -- | 0.6626 | -- | 3.16 | -0.2787 | -0.2787 | 0.1521 | 0.4452 | 0.1395 | 1.34 | 4.82 | 129,629.00 | -22.80 | -21.94 | -25.70 | -24.71 | 14.04 | 14.73 | -163.46 | -248.95 | 3.42 | -53.95 | 0.2639 | -- | -46.94 | 75.18 | -43.29 | -- | -10.93 | -- |
| genOway SA | 21.42m | 1.26m | 34.78m | 128.00 | 26.14 | 1.84 | 9.28 | 1.62 | 0.1435 | 0.1435 | 2.45 | 2.04 | 0.6658 | 1.39 | 3.26 | 161,089.30 | 3.90 | 0.2166 | 5.40 | 0.3048 | 92.34 | 94.82 | 5.86 | 0.4177 | 1.81 | -- | 0.2639 | -- | 17.55 | 13.16 | 101.55 | 22.35 | -14.31 | -- |
| Gensight Biologics SA | 804.00k | -20.11m | 36.81m | 11.00 | -- | -- | -- | 45.79 | -0.3537 | -0.3537 | 0.0123 | -0.2402 | 0.0507 | -- | 21.73 | 50,250.00 | -126.79 | -79.44 | -- | -144.54 | -- | -- | -2,501.00 | -1,036.27 | -- | -1,250.38 | -- | -- | -50.93 | -- | 5.09 | -- | -58.28 | -- |
| Novacyt SA | 22.31m | -44.90m | 40.96m | 240.00 | -- | 0.4836 | -- | 1.84 | -0.6357 | -0.6405 | 0.3159 | 1.20 | 0.1603 | -3.66 | 1.02 | 82,619.26 | -32.27 | 10.94 | -38.44 | 14.49 | 153.78 | 61.98 | -201.27 | 17.64 | 3.82 | -23.91 | 0.1573 | -- | -44.97 | -0.9408 | -25.22 | -- | 2.09 | -- |
| Abionyx Pharma SA | 4.86m | -3.36m | 43.52m | 61.00 | -- | 4.25 | -- | 8.96 | -0.1063 | -0.1063 | 0.1548 | 0.2934 | 0.3316 | 21.80 | 6.05 | 80,264.46 | -22.93 | -18.82 | -33.15 | -28.87 | 19.19 | 14.32 | -69.15 | -128.54 | 2.22 | -114.07 | 0.2513 | -- | -11.65 | 92.84 | 16.36 | -- | 41.40 | -- |
| Eurofins-Cerep SA | 42.42m | 7.25m | 99.87m | 218.00 | 13.77 | 1.48 | 10.80 | 2.35 | 1,438.10 | 1,438.10 | 8,415.76 | 13,378.57 | 0.5618 | 1.52 | 5.41 | 186,032.70 | 9.61 | 14.21 | 11.08 | 17.51 | 85.48 | 73.61 | 17.10 | 19.77 | 6.89 | -- | 0.0047 | -- | -7.47 | 11.60 | -33.72 | 14.64 | -- | -- |
| Transgene SA | -100.00bn | -100.00bn | 103.45m | 162.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -24.81 | -- | -29.79 | -- | -- | -- | -193.24 | -- | -- | -- | -- | -23.68 | 1.51 | 31.94 | -- | 14.44 | -- |
| Maat Pharma SA | 2.57m | -24.14m | 110.23m | 50.00 | -- | 4.30 | -- | 42.88 | -2.03 | -2.03 | 0.2161 | 1.84 | 0.0511 | 6.50 | 2.18 | 51,420.00 | -47.94 | -35.49 | -64.64 | -42.98 | 67.87 | -- | -938.86 | -1,157.54 | 2.75 | -47.95 | 0.4014 | -- | 55.80 | -- | -43.78 | -- | 30.30 | -- |
| Innate Pharma SA | 24.85m | -34.05m | 123.72m | 168.00 | -- | 4.30 | -- | 4.98 | -0.4215 | -0.4215 | 0.3078 | 0.3557 | 0.1418 | -- | 14.93 | 138,826.80 | -19.43 | -8.83 | -24.80 | -12.11 | 88.00 | 93.17 | -137.03 | -55.55 | -- | -- | 0.7527 | -- | 4.68 | -8.27 | 86.94 | -- | 10.50 | -- |
| Cellectis SA | 34.41m | -99.60m | 124.10m | 235.00 | -- | 1.00 | -- | 3.61 | -1.40 | -1.10 | 0.3995 | 1.71 | 0.119 | -- | 6.23 | 146,440.00 | -35.11 | -24.08 | -53.69 | -30.69 | -- | -64.64 | -294.96 | -308.24 | -- | -2.77 | 0.452 | -- | -64.26 | -15.57 | -20.55 | -- | -26.15 | -- |
| Adocia SA | 523.00k | -20.72m | 125.94m | 79.00 | -- | -- | -- | 240.80 | -1.53 | -1.53 | 0.0382 | -0.5123 | 0.0234 | 1.15 | 3.15 | 6,705.13 | -92.78 | -43.08 | -- | -72.93 | 32.50 | -- | -3,960.99 | -514.53 | 0.8927 | -2.79 | 2.38 | -- | -81.22 | -46.13 | -206.65 | -- | -27.60 | -- |
| Holder | Shares | % Held |
|---|---|---|
| BFT Investment Managers SAas of 30 Sep 2024 | 818.58k | 0.62% |
| Soci�t� G�n�rale Gestion SAas of 30 Sep 2024 | 183.37k | 0.14% |
| Erasmus Gestion SASas of 03 Sep 2024 | 174.74k | 0.13% |
| Financi�re Arbevel SAas of 30 Dec 2022 | 87.00k | 0.07% |
| Strat�ge Finance SAas of 28 Mar 2024 | 0.00 | 0.00% |
